Ocular Pain – Pipeline Review, H1 2012

Date: May 28, 2012
Pages: 41
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OACB2EECFFEEN
Leaflet:

Download PDF Leaflet

Ocular Pain – Pipeline Review, H1 2012
Ocular Pain – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Ocular Pain - Pipeline Review, H1 2012', provides an overview of the Ocular Pain therapeutic pipeline. This report provides information on the therapeutic development for Ocular Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Pain. 'Ocular Pain - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Ocular Pain.
  • A review of the Ocular Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Ocular Pain pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Ocular Pain.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Ocular Pain therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords

Ocular Pain Therapeutic Products under Development, Key Players in Ocular Pain Therapeutics, Ocular Pain Pipeline Overview, Ocular Pain Pipeline, Ocular Pain Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Ocular Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Ocular Pain
Ocular Pain Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Ocular Pain Therapeutics – Products under Development by Companies
Companies Involved in Ocular Pain Therapeutics Development
Sylentis
Novagali Pharma SA
ISTA Pharmaceuticals, Inc.
InSite Vision Incorporated
Ocular Pain – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BromSite - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nova-22038 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYL1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prolensa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ocular Pain Therapeutics – Drug Profile Updates
Ocular Pain Therapeutics - Dormant Products
Ocular Pain – Product Development Milestones
Featured News & Press Releases
May 10, 2012: Ista Pharma Highlights PROLENSA Clinical Data At ARVO Annual Meeting
Apr 23, 2012: ISTA Pharmaceuticals Highlights PROLENSA Clinical Data At 2012 ASCRS Symposium And Congress
Oct 13, 2011: ISTA Pharmaceuticals Announces Statistically Significant Phase III Results For PROLENSA
Sep 26, 2011: Bausch + Lomb Launches Lotemax Ointment
Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery
Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling
Nov 17, 2010: ISTA Pharmaceuticals Receives Three-Year Market Exclusivity For BROMDAY
Oct 20, 2010: Quark Initiates Phase I Study Of QPI-1007 For Treatment Of Ischemic Optic Neuropathy
Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Ocular Pain, H1 2012
Products under Development for Ocular Pain – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Sylentis, H1 2012
Novagali Pharma SA, H1 2012
ISTA Pharmaceuticals, Inc., H1 2012
InSite Vision Incorporated, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Ocular Pain Therapeutics – Drug Profile Updates
Ocular Pain Therapeutics – Dormant Products

LIST OF FIGURES

Number of Products under Development for Ocular Pain, H1 2012
Products under Development for Ocular Pain – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Ocular Pain - Pipeline Review, Q2 2011 US$ 500.00 May, 2011 · 32 pages
Ocular Inflammation - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 45 pages
Osteoarthritis Pain - Pipeline Review, H2 2013 US$ 2,000.00 Aug, 2013 · 148 pages
Acute Pain - Pipeline Review, H2 2013 US$ 2,000.00 Aug, 2013 · 140 pages
Ocular Inflammation - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages

Ask Your Question

Ocular Pain – Pipeline Review, H1 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: